eCite Digital Repository

Routine prophylactic cardioprotective therapy should be given to all recipients at risk of cardiotoxicity from cancer chemotherapy

Citation

Abdel-Qadir, H and Nolan, MT and Thavendiranathan, P, Routine prophylactic cardioprotective therapy should be given to all recipients at risk of cardiotoxicity from cancer chemotherapy, Canadian Journal of Cardiology, 32, (7) pp. 921-925. ISSN 0828-282X (2016) [Refereed Article]

Copyright Statement

Copyright 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

DOI: doi:10.1016/j.cjca.2016.04.010

Abstract

The inevitability of cardiac injury in many patients treated for cancer mandates strategies to mitigate the effect of cancer treatment on the heart. In this article we argue that the best approach to prevent cardiotoxicity is universal primary prevention for everyone at risk for irreversible myocardial injury. Our viewpoint is on the basis of 5 major arguments that we discuss in detail in this article. We outline the shortcomings of alternate strategies for prevention and highlight that the strongest existing evidence today supports our viewpoint. In particular, data from multiple randomized controlled trials indicate that most patients who receive anthracyclines are at risk, and should be accordingly considered for primary prevention.

Item Details

Item Type:Refereed Article
Research Division:Medical and Health Sciences
Research Group:Cardiorespiratory Medicine and Haematology
Research Field:Cardiology (incl. Cardiovascular Diseases)
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Cardiovascular System and Diseases
Author:Nolan, MT (Mr Mark Nolan)
ID Code:120008
Year Published:2016
Web of Science® Times Cited:1
Deposited By:Menzies Institute for Medical Research
Deposited On:2017-08-08
Last Modified:2017-09-22
Downloads:0

Repository Staff Only: item control page